Bull
$100.37
情境價格
$129.090
+0.439 (+0.34%)收盤時
Mesa Laboratories, Inc. designs and manufactures life sciences tools and critical control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. The Company's segments include Sterilization and Disinfection Control, Clinical Genomics, Biopharmaceutical Development, and Calibration Solutions. Sterilization and Disinfection Control segment manufactures and sells biological, chemical and cleaning indicators. Clinical Genomics segment develops, manufactures and sells genetic analysis tools and related consumables and services. Biopharmaceutical Development segment develops, manufactures, sells and services automated systems for protein analysis and peptide synthesis solutions. Calibration Solutions segment develops, manufactures, sells and services control products using principles of advanced metrology to enable customers to measure and calibrate critical parameters in applications, such as renal care, environmental and process monitoring.
Mesa Laboratories Inc is a good buy right now due to its recent price increase of 3.47% over the last five days and a strong gross margin of 66.23% in Q4 2026, which suggests robust profitability. The current RSI of 83.95 indicates strong momentum, although it is approaching overbought territory. The main risk is the recent earnings miss, where revenue fell short by approximately $1.48 million, leading to a significant stock price drop of 19.5% following the Q4 report.
Wells Fargo
$94
2026-02-04
Wells Fargo
2026-02-04
目標價
$94
Wells Fargo
$83
2025-12-15
Wells Fargo
2025-12-15
目標價
$83
Jefferies
$115
2025-11-07
Jefferies
2025-11-07
目標價
$115
Wells Fargo
$67
2025-08-07
Wells Fargo
2025-08-07
目標價
$67
Wells Fargo
$100
2025-05-30
Wells Fargo
2025-05-30
目標價
$100
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

Mesa Laboratories Reports Q1 2027 Earnings with Mixed Results

Mesa Laboratories to Release Q1 2027 Financial Results on August 10, 2026

Mesa Laboratories Declares Quarterly Dividend of $0.16

Mesa Laboratories Declares Quarterly Dividend

Mesa Laboratories Shares Plunge 19.5% Following Q4 Earnings Report
Mesa Laboratories, Inc. designs and manufactures life sciences tools and critical control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. The Company's segments include Sterilization and Disinfection Control, Clinical Genomics, Biopharmaceutical Development, and Calibration Solutions. Sterilization and Disinfection Control segment manufactures and sells biological, chemical and cleaning indicators. Clinical Genomics segment develops, manufactures and sells genetic analysis tools and related consumables and services. Biopharmaceutical Development segment develops, manufactures, sells and services automated systems for protein analysis and peptide synthesis solutions. Calibration Solutions segment develops, manufactures, sells and services control products using principles of advanced metrology to enable customers to measure and calibrate critical parameters in applications, such as renal care, environmental and process monitoring. It operates in the Healthcare sector (INDUSTRIAL INSTRUMENTS FOR MEASUREMENT, DISPLAY, A industry).
Mesa Laboratories Inc is a good buy right now due to its recent price increase of 3.47% over the last five days and a strong gross margin of 66.23% in Q4 2026, which suggests robust profitability. The current RSI of 83.95 indicates strong momentum, although it is approaching overbought territory. The main risk is the recent earnings miss, where revenue fell short by approximately $1.48 million, leading to a significant stock price drop of 19.5% following the Q4 report.
2 analysts cover MLAB: 1 rate it Buy, 1 Hold and 0 Sell. The average price target is 99.00.
本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。